CN109096374B - 一种抑制肺癌转移的合成寡肽 - Google Patents
一种抑制肺癌转移的合成寡肽 Download PDFInfo
- Publication number
- CN109096374B CN109096374B CN201811128218.XA CN201811128218A CN109096374B CN 109096374 B CN109096374 B CN 109096374B CN 201811128218 A CN201811128218 A CN 201811128218A CN 109096374 B CN109096374 B CN 109096374B
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- oligopeptide
- cells
- metastasis
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 64
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 64
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 64
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 53
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 53
- 206010027476 Metastases Diseases 0.000 title abstract description 18
- 230000009401 metastasis Effects 0.000 title abstract description 18
- 230000002401 inhibitory effect Effects 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 108010051335 Lipocalin-2 Proteins 0.000 abstract description 16
- 102000013519 Lipocalin-2 Human genes 0.000 abstract description 14
- 230000014509 gene expression Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 8
- 230000009545 invasion Effects 0.000 abstract description 8
- 238000013508 migration Methods 0.000 abstract description 8
- 230000005012 migration Effects 0.000 abstract description 8
- 230000035755 proliferation Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 6
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 4
- 230000034994 death Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 4
- 230000036210 malignancy Effects 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 230000000630 rising effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 50
- 230000000694 effects Effects 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 238000012258 culturing Methods 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 7
- 230000003698 anagen phase Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- YTWNSIDWAFSEEI-RWMBFGLXSA-N Pro-His-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@@H]3C(=O)O YTWNSIDWAFSEEI-RWMBFGLXSA-N 0.000 description 2
- YLHFIMLKNPJRGY-BVSLBCMMSA-N Tyr-Arg-Trp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O YLHFIMLKNPJRGY-BVSLBCMMSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012946 outsourcing Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
- HJAICMSAKODKRF-GUBZILKMSA-N Arg-Cys-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O HJAICMSAKODKRF-GUBZILKMSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- VENMDXUVHSKEIN-GUBZILKMSA-N Arg-Ser-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O VENMDXUVHSKEIN-GUBZILKMSA-N 0.000 description 1
- ISVACHFCVRKIDG-SRVKXCTJSA-N Arg-Val-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O ISVACHFCVRKIDG-SRVKXCTJSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- BTSPOOHJBYJRKO-CIUDSAMLSA-N Gln-Asp-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BTSPOOHJBYJRKO-CIUDSAMLSA-N 0.000 description 1
- LUGUNEGJNDEBLU-DCAQKATOSA-N Gln-Met-Arg Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N LUGUNEGJNDEBLU-DCAQKATOSA-N 0.000 description 1
- XXCDTYBVGMPIOA-FXQIFTODSA-N Glu-Asp-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XXCDTYBVGMPIOA-FXQIFTODSA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- AVQNTYBAFBKMDL-WDSOQIARSA-N His-Pro-Trp Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O AVQNTYBAFBKMDL-WDSOQIARSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- ZCWWVXAXWUAEPZ-SRVKXCTJSA-N Lys-Met-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZCWWVXAXWUAEPZ-SRVKXCTJSA-N 0.000 description 1
- ZJSZPXISKMDJKQ-JYJNAYRXSA-N Lys-Phe-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=CC=C1 ZJSZPXISKMDJKQ-JYJNAYRXSA-N 0.000 description 1
- XFANQCRHTMOEAP-WDSOQIARSA-N Lys-Pro-Trp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XFANQCRHTMOEAP-WDSOQIARSA-N 0.000 description 1
- GVKINWYYLOLEFQ-XIRDDKMYSA-N Lys-Trp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O GVKINWYYLOLEFQ-XIRDDKMYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 1
- ZWJKVFAYPLPCQB-UNQGMJICSA-N Phe-Arg-Thr Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)Cc1ccccc1)C(O)=O ZWJKVFAYPLPCQB-UNQGMJICSA-N 0.000 description 1
- 108010025216 RVF peptide Proteins 0.000 description 1
- ZVBCMFDJIMUELU-BZSNNMDCSA-N Ser-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)N ZVBCMFDJIMUELU-BZSNNMDCSA-N 0.000 description 1
- SCQBNMKLZVCXNX-ZFWWWQNUSA-N Trp-Arg-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N SCQBNMKLZVCXNX-ZFWWWQNUSA-N 0.000 description 1
- KZTLJLFVOIMRAQ-IHPCNDPISA-N Trp-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KZTLJLFVOIMRAQ-IHPCNDPISA-N 0.000 description 1
- GFZQWWDXJVGEMW-ULQDDVLXSA-N Tyr-Arg-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O GFZQWWDXJVGEMW-ULQDDVLXSA-N 0.000 description 1
- PGEFRHBWGOJPJT-KKUMJFAQSA-N Tyr-Lys-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O PGEFRHBWGOJPJT-KKUMJFAQSA-N 0.000 description 1
- HNWQUBBOBKSFQV-AVGNSLFASA-N Val-Arg-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N HNWQUBBOBKSFQV-AVGNSLFASA-N 0.000 description 1
- AIWLHFZYOUUJGB-UFYCRDLUSA-N Val-Phe-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 AIWLHFZYOUUJGB-UFYCRDLUSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010094001 arginyl-tryptophyl-arginine Proteins 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 108010084389 glycyltryptophan Proteins 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种抑制肺癌转移的合成寡肽。肺癌是全球发病率和死亡率最高的恶性肿瘤之一,近年来其发病率在我国呈上升和年轻化趋势,其发生、发展和转移均涉及极其复杂的多基因调控异常过程。因此,研究肺癌的病因、发病机制具有重要的临床意义。侵袭和转移是恶性肿瘤导致患者死亡的主要原因。本发明提供的寡肽可以通过抑制NGAL基因表达抑制肺癌细胞的增殖、迁移和侵袭,可以制成防治肺癌转移、治疗肺癌的药物。
Description
技术领域
本发明属于化学领域,涉及一种抑制肺癌转移的合成寡肽。
背景技术
肺癌是全球发病率和死亡率最高的恶性肿瘤之一,近年来其发病率在我国呈上升和年轻化趋势,其发生、发展和转移均涉及极其复杂的多基因调控异常过程。因此,研究肺癌的病因、发病机制具有重要的临床意义。
侵袭和转移是恶性肿瘤导致患者死亡的主要原因。
发明内容
本发明旨在提供一种抑制肺癌转移的合成寡肽。
本发明技术方案如下:
一种寡肽,其特征在于:序列如Sequence NO.4所示。
上述寡肽用作NGAL基因表达抑制剂的用途。
上述寡肽用于制备防治肺癌转移的药物的用途。
上述寡肽用于制备治疗肺癌的药物的用途。
有益效果:
肺癌是全球发病率和死亡率最高的恶性肿瘤之一,近年来其发病率在我国呈上升和年轻化趋势,其发生、发展和转移均涉及极其复杂的多基因调控异常过程。因此,研究肺癌的病因、发病机制具有重要的临床意义。侵袭和转移是恶性肿瘤导致患者死亡的主要原因。本发明提供的寡肽可以通过抑制NGAL基因表达抑制肺癌细胞的增殖、迁移和侵袭,可以制成防治肺癌转移、治疗肺癌的药物。
附图说明
图1为寡肽1~5对肺癌A549细胞中NGAL基因表达的影响;
图2为寡肽1~5对肺癌A549细胞增殖的影响;
图3为寡肽1~5对肺癌A549细胞迁移能力的影响;
图4为寡肽1~5对肺癌A549细胞侵袭能力的影响。
具体实施方式
下面结合附图和实施例具体介绍本发明实质性内容,但并不以此限定本发明的保护范围。
一、实验材料
寡肽1~5委托外包机构合成,纯度不低于95%,序列如下:
寡肽1:RCRVFYKPWVRHQMRGRYN(Sequence NO.1);
寡肽2:HPWYRKWNYRVRWRGWFMR(Sequence NO.2);
寡肽3:QDRKWSYKSSYFRKRGRSRT(Sequence NO.3);
寡肽4:PHPEGEFRTKMEYRWEYRVR(Sequence NO.4);
寡肽5:PHPEDEFATKFEYRWGYRVR(Sequence NO.5)。
胎牛血清、DMEM高糖培养基购自Gbico公司;TRIzol试剂购自Invitrogen公司;反转录试剂盒及定量PCR试剂盒购自TAKARA公司;Tanswell侵袭小室购自millpore公司。
NGAL、GAPDH的RT-PCR引物委托外包机构合成。
二、实验方法
1、细胞培养
肺癌A549细胞用含10%胎牛血清的DMEM培养基置37℃、5%CO2条件下培养。
2、分组及给药
取对数生长期的肺癌A549细胞,随机分组给药:
对照组:使用含10%胎牛血清的DMEM培养基培养;
寡肽1组:在对照组基础上添加5μM寡肽1培养;
寡肽2组:在对照组基础上添加5μM寡肽2培养;
寡肽3组:在对照组基础上添加5μM寡肽3培养;
寡肽4组:在对照组基础上添加5μM寡肽4培养;
寡肽5组:在对照组基础上添加5μM寡肽5培养。
3、寡肽对肺癌A549细胞中NGAL基因表达的影响
将肺癌A549细胞培养于含10%胎牛血清DMEM培养基中,取对数生长期的细胞消化、计数,2×105个/孔铺于24孔板,待细胞贴壁后,按照上述分组方法分组并更换为对应的培养基培养,每组设3个平行孔,继续培养48h,弃去上清,收集细胞,按TRIzol试剂盒说明书提取细胞总RNA,用紫外分光光度计分别测定RNA浓度,根据吸光度OD260和OD280比值判定纯度。分别取5μg细胞总RNA,按反转录试剂盒说明书反转录成cDNA,以cDNA为模板应用。反应条件为:94℃预热3min,然后94℃30s,52℃30s,72℃50s,扩增29个循环,72℃延伸10min。PCR产物进行1%琼脂糖凝胶电泳,通过Image J图像分析软件分析各电泳条带的灰度值,以目的条带的灰度值与GAPDH内参照条带的灰度值的比值表示目的基因mRNA的相对表达量。NGAL的上游引物为5′-GAAGACAAAGACCCGCAAAAG-3′,其下游引物序列为5′-CTGGCAACCTGGAACAAAAG-3′。内参GAPDH的上游引物序列为5′-ACCACAGTCCATGCCATCAC-3′,下游引物为5′-TCCACCACCCTGTGCTGTA-3′。
4、MTT法检测寡肽对肺癌A549细胞的增殖抑制作用
将肺癌A549细胞培养于含10%胎牛血清DMEM培养基中,取对数生长期的细胞消化、计数,4×104个/孔铺于96孔板,待细胞贴壁后,按照上述分组方法分组并更换为对应的培养基培养,每组设6个平行孔,继续培养48h,弃去上清,各孔加入无血清培养基溶解的MTT,孵育4h,以二甲基亚砜溶解后于酶标仪570nm处测量吸光度值。
5、细胞迁移能力检测
将肺癌A549细胞培养于含10%胎牛血清DMEM培养基中,取对数生长期的细胞消化,离心,弃上清,采用含体积分数10%胎牛血清的DMEM培养基重悬细胞,制成单细胞悬液,按照上述分组及给药方法于37℃、体积分数5%CO2饱和湿度培养箱中培养48h。
培养48h后,消化收集细胞,用无血清DMEM培养基制成细胞悬液,以2.5×104个/孔的密度接种于6孔板,当细胞呈单层贴壁且接近100%融合时,使用10μl无菌移液器头在6孔板中划痕,清洗悬浮脱落细胞后,用无血清培养液,放置于37℃、5%CO2培养箱内,分别于划痕后0和48h在倒置光学显微镜下拍照,计算其划痕愈合率,实验重复3次。划痕愈合率=(0h划痕距离-48h后划痕距离)/0h划痕距离×100%。
6、细胞侵袭能力检测
将肺癌A549细胞培养于含10%胎牛血清DMEM培养基中,取对数生长期的细胞消化,离心,弃上清,采用含体积分数10%胎牛血清的DMEM培养基重悬细胞,制成单细胞悬液,按照上述分组及给药方法于37℃、体积分数5%CO2饱和湿度培养箱中培养48h。
培养48h后,消化收集细胞,用无血清DMEM培养基制备细胞悬液,以2.5×105/孔的密度铺于Transwell小室上层腔室。然后,将含体积分数20%胎牛血清的DMEM培养基加入Transwell小室下层腔室。培养24h后,用棉签从Transwell小室上层腔室移走非侵袭的细胞,取Transwell小室,以PBS洗涤3遍,甲醇固定30min,采用0.1%结晶紫染色30min,于倒置光学显微镜观察计数。随机选取5个视野计数。
7、统计学分析
采用SPSS 19.0统计学软件,实验重复3次,数据资料用均值±标准差表示,样本均数比较采用组间t检验。P<0.05为差异有显著性意义。
三、实验结果
1、寡肽1~5对肺癌A549细胞中NGAL基因表达的影响
结果见表1和图1,寡肽1~4可以显著抑制肺癌A549细胞中NGAL基因的表达水平,而寡肽5对肺癌A549细胞中NGAL基因的表达无明显抑制作用。
表1寡肽1~5对肺癌A549细胞中NGAL基因表达的影响
中性粒细胞明胶酶相关脂质运载蛋白(NGAL)是lipocalin家族的一个成员。研究发现,NGAL在肺癌组织中高表达,有可能是治疗肺癌的一个潜在靶点(参考文献:肺鳞癌及腺癌中NGAL表达的免疫组化研究,实验与检验医学,2014年01期)。
2、寡肽1~5对肺癌A549细胞增殖的影响
结果见表2和图2,寡肽1~4可以显著抑制肺癌A549细胞的增殖,而寡肽5对肺癌A549细胞的增殖无明显抑制作用。
表2寡肽1~5对肺癌A549细胞增殖的影响
3、寡肽1~5对肺癌A549细胞迁移能力的影响
结果见表3和图3,寡肽1~4可以显著抑制肺癌A549细胞的迁移能力,而寡肽5对肺癌A549细胞的迁移能力无明显抑制作用。
表3寡肽1~5对肺癌A549细胞迁移能力的影响
4、寡肽1~5对肺癌A549细胞侵袭能力的影响
结果见表4和图4,寡肽1~4可以显著抑制肺癌A549细胞的侵袭能力,而寡肽5对肺癌A549细胞的侵袭能力无明显抑制作用。
表4寡肽1~5对肺癌A549细胞侵袭能力的影响
肺癌是全球发病率和死亡率最高的恶性肿瘤之一,近年来其发病率在我国呈上升和年轻化趋势,其发生、发展和转移均涉及极其复杂的多基因调控异常过程。因此,研究肺癌的病因、发病机制具有重要的临床意义。侵袭和转移是恶性肿瘤导致患者死亡的主要原因。本发明提供的寡肽可以通过抑制NGAL基因表达抑制肺癌细胞的增殖、迁移和侵袭,可以制成防治肺癌转移、治疗肺癌的药物。
上述实施例的作用在于具体介绍本发明的实质性内容,但本领域技术人员应当知道,不应将本发明的保护范围局限于该具体实施例。
序列表
<110> 淮安安莱生物科技有限公司
<120> 一种抑制肺癌转移的合成寡肽
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Arg Cys Arg Val Phe Tyr Lys Pro Trp Val Arg His Gln Met Arg Gly
1 5 10 15
Arg Tyr Asn
<210> 2
<211> 19
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
His Pro Trp Tyr Arg Lys Trp Asn Tyr Arg Val Arg Trp Arg Gly Trp
1 5 10 15
Phe Met Arg
<210> 3
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Gln Asp Arg Lys Trp Ser Tyr Lys Ser Ser Tyr Phe Arg Lys Arg Gly
1 5 10 15
Arg Ser Arg Thr
20
<210> 4
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Pro His Pro Glu Gly Glu Phe Arg Thr Lys Met Glu Tyr Arg Trp Glu
1 5 10 15
Tyr Arg Val Arg
20
<210> 5
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Pro His Pro Glu Asp Glu Phe Ala Thr Lys Phe Glu Tyr Arg Trp Gly
1 5 10 15
Tyr Arg Val Arg
20
Claims (2)
1.一种寡肽,其特征在于:序列如Sequence NO. 4所示。
2.权利要求1所述的寡肽用于制备治疗肺癌的药物的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811128218.XA CN109096374B (zh) | 2018-09-27 | 2018-09-27 | 一种抑制肺癌转移的合成寡肽 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811128218.XA CN109096374B (zh) | 2018-09-27 | 2018-09-27 | 一种抑制肺癌转移的合成寡肽 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109096374A CN109096374A (zh) | 2018-12-28 |
CN109096374B true CN109096374B (zh) | 2022-11-18 |
Family
ID=64867135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811128218.XA Active CN109096374B (zh) | 2018-09-27 | 2018-09-27 | 一种抑制肺癌转移的合成寡肽 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109096374B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1974768A (zh) * | 2006-10-24 | 2007-06-06 | 汕头大学医学院 | 人肺癌细胞ngal基因启动子区转录调控元件 |
CN101421622A (zh) * | 2006-02-17 | 2009-04-29 | 儿童医学中心公司 | 作为癌症生物标志物的游离ngal |
WO2012042061A1 (en) * | 2010-10-01 | 2012-04-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
WO2015177175A2 (en) * | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
-
2018
- 2018-09-27 CN CN201811128218.XA patent/CN109096374B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101421622A (zh) * | 2006-02-17 | 2009-04-29 | 儿童医学中心公司 | 作为癌症生物标志物的游离ngal |
CN1974768A (zh) * | 2006-10-24 | 2007-06-06 | 汕头大学医学院 | 人肺癌细胞ngal基因启动子区转录调控元件 |
WO2012042061A1 (en) * | 2010-10-01 | 2012-04-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
WO2015177175A2 (en) * | 2014-05-22 | 2015-11-26 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
Non-Patent Citations (1)
Title |
---|
沉默NGAL基因对肺癌细胞迁移及侵袭的影响;唐健等;《中国肺癌杂志》;20150430;第18卷(第4期);第187-192页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109096374A (zh) | 2018-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107805663B (zh) | Lnc03729基因作为生物标志物在肺腺癌预诊断试剂中的应用 | |
Gao et al. | Long non-coding RNA LINC00324 exerts pro-tumorigenic effects on liver cancer stem cells by up-regulating Fas ligand via PU box binding protein | |
Chen et al. | LncRNA MEG3 inhibits self-renewal and invasion abilities of oral cancer stem cells by sponging miR-421 | |
Zhang et al. | Low expression of lncRNA MEG3 promotes the progression of oral squamous cell carcinoma by targeting miR-21. | |
CN107164554B (zh) | Asprv1作为生物标志物在喉鳞癌诊疗中的应用 | |
CN109096374B (zh) | 一种抑制肺癌转移的合成寡肽 | |
CN109206485B (zh) | 一种防治肺癌转移的寡肽 | |
CN109096373B (zh) | 合成寡肽及其用途 | |
CN109180789B (zh) | 一种寡肽及制药应用 | |
CN104911271A (zh) | 基于肽核酸探针的Wnt信号通路中Pygo2及FoxM1基因表达的检测试剂、PCR检测方法及应用 | |
CN109200041B (zh) | 香附薁酮用于制备抑制sirt1基因表达治疗食管鳞状细胞癌的药物的用途 | |
Greco et al. | Gene expression analysis in SV-40 immortalized human corneal epithelial cells cultured with an air-liquid interface | |
Zhang et al. | miRNA-627 inhibits cell proliferation and cell migration, promotes cell apoptosis in prostate cancer cells through upregulating MAP3K1, PTPRK and SRA1 | |
CN108165631A (zh) | 一种骨肉瘤的生物标志物syt12及其应用 | |
CN110577952B (zh) | 干扰长非编码RNA的siRNA在制备治疗乳腺癌药物中的应用 | |
CN108085388B (zh) | 一种与骨肉瘤发生发展相关的基因及其应用 | |
CN107354210B (zh) | Cmya5基因及其表达产物在喉鳞癌中的应用 | |
CN111635939A (zh) | 一种检测rbp1基因或蛋白的产品及应用 | |
CN110964028A (zh) | 小槐花中柠檬酚的提取方法及其用途 | |
CN114053270B (zh) | 泛素结合酶e2t的小分子抑制剂 | |
CN110951880A (zh) | 检测下咽癌lncRNA标志物的试剂在制备诊断下咽癌产品中的应用 | |
AU2020342299B2 (en) | Tumour marker aquaporin 2 protein and application thereof | |
CN117298083B (zh) | D-乳酸在制备治疗和/或预防食管鳞状细胞癌药物中的用途 | |
CN118127022B (zh) | 变异链球菌环状RNA circcsbD及应用、其过表达菌株及构建方法和应用 | |
CN113604569B (zh) | miR-6883-3p在制备用于抗肝癌或肝癌预后评估产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221102 Address after: 518000 Financial Office of Land Watson Life Technology Center, Baguang Community, Kuichong Street, Dapeng New District, Shenzhen, Guangdong Applicant after: Shenzhen Letu Watson Precision Medical Co.,Ltd. Address before: 223001 room 112, 191 Hanhou Avenue, qingjiangpu District, Huai'an City, Jiangsu Province Applicant before: HUAI'AN ANLAI BIOTECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |